Alopecia areata

New England Journal of Medicine

Volumn 366, Issue 16, 2012, Pages 1515-1525

  Gilhar, Amos ^a,b   Etzioni, Amos ^b,c   Paus, Ralf ^d,e  

^a Flieman Geriatric Rehabilitation Hospital   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Meyer's Children's Hospital   (Israel)

^d UNIVERSITY OF LÜBECK   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DIPHENCYPRONE; DITHRANOL; GLUCOCORTICOID; METHYLPREDNISOLONE; MINOXIDIL; PREDNISOLONE; SQUARIC ACID DIBUTYL ESTER; TRIAMCINOLONE;

ALOPECIA AREATA; APPLICATION SITE DISCOLORATION; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTACT DERMATITIS; DEPIGMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; EPILUMINESCENCE MICROSCOPY; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FOLLICULITIS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HAIR FOLLICLE; HAIR GROWTH; HISTOCOMPATIBILITY GENE; HUMAN; IMMUNOBIOLOGY; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN ATROPHY; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT PLANNING;

EID: 84859877614     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1103442     Document Type: Article

References (92)

1. Picardi A, Pasquini P, Cattaruzza MS, et al. Psychosomatic factors in first-onset alopecia areata. Psychosomatics 2003;44: 374-81. (Pubitemid 37071924)
2. Paus R, Arck PJ. Neuroendocrine perspectives in alopecia areata: does stress play a role? J Invest Dermatol 2009;129: 1324-6.
3. Delamere FM, Sladden MM, Dobbins HM, et al. Interventions for alopecia areata. Cochrane Database Syst Rev 2008;2: CD004413.
4. Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ 2010; 341:c3671.
5. Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010;62:191-202.
6. Garg S, Messenger AG. Alopecia areata: evidence based treatments. Semin Cutan Med Surg 2009;28:15-8.
7. McElwee KJ, Freyschmidt-Paul P, Hoffmann R, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol 2005; 124:947-57. (Pubitemid 40629095)
8. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 1998;101:62-7. (Pubitemid 28058903)
9. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007;117: 2019-27. (Pubitemid 47219540)
10. McMichael AJ, Pearce DJ, Wasserman D, et al. Alopecia in the United States: outpatient utilization and common prescribing pattern. J Am Acad Dermatol 2007;57:Suppl:S49-S51. (Pubitemid 47048445)
11. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992; 128:702.
12. Finner AM. Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol Ther 2011;24:348-54.
13. Kyriakis KP, Paltatzidou K, Kosma E, Sofouri E, Tadros A, Rachioti E. Alopecia areata prevalence by gender and age. J Eur Acad Dermatol Venereol 2009;23:572-3.
14. Xiao FL, Yang S, Liu JB, et al. The epidemiology of childhood alopecia areata in China: a study of 226 patients. Pediatr Dermatol 2006;23:13-8.
15. Barahmani N, Schabath MB, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009;61:581-91.
16. Chu SY, Chen YJ, Tseng WC, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol 2011;65:949-56.
17. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006;20:1055-60. (Pubitemid 44425959)
18. Kuchabal SD, Kuchabal DS. Alopecia areata associated with localized vitiligo. Case Rep Dermatol 2010;2:27-31.
19. Kurtev A, Iliev E. Thyroid autoimmunity in children and adolescents with alopecia areata. Int J Dermatol 2005;44:457-61. (Pubitemid 40867548)
20. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999;341:491-7. (Pubitemid 29372890)
21. Schneider MR, Schmidt-Ullrich R, Paus R. The hair follicle as a dynamic miniorgan. Curr Biol 2009;19:R132-R142.
22. Tosti A, Colombati S, De Padova MP, Guidi SG, Tosti G, Maccolini E. Retinal pigment epithelium function in alopecia areata. J Invest Dermatol 1986;86:553-5. (Pubitemid 16052557)
23. Tobin DJ. The cell biology of human hair follicle pigmentation. Pigment Cell Melanoma Res 2011;24:75-88.
24. Cotsarelis G. Epithelial stem cells: a folliculocentric view. J Invest Dermatol 2006;126:1459-68.
25. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003;139:1555-9. (Pubitemid 37523073)
26. The dermis and the subcutis. In: Weedon D. Weedon's skin pathology. Vol. I. 3rd ed. London: Churchill Livingstone/ Elsevier, 2009:422-4.
27. Khoury EL, Price VH, Greenspan JS. HLA-DR expression by hair follicle keratinocytes in alopecia areata: evidence that it is secondary to the lymphoid infiltration. J Invest Dermatol 1988;90:193-200. (Pubitemid 18054990)
28. Dy LC, Whiting DA. Histopathology of alopecia areata, acute and chronic: why is it important to the clinician? Dermatol Ther 2011;24:369-74.
29. Christoph T, Müller-Röver S, Audring H, et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol 2000;142:862-73. (Pubitemid 30304594)
30. Paus R, Nickoloff BJ, Ito T. A 'hairy' privilege. Trends Immunol 2005;26:32-40. (Pubitemid 40051990)
31. Meyer KC, Klatte JE, Dinh HV, et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 2008;159:1077-85.
32. Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol 2004;164:623-34. (Pubitemid 38364677)
33. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65. (Pubitemid 44401493)
34. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006;7:354-9.
35. Höglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol 2010;10:724-34.
36. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002;20:853-85. (Pubitemid 34293442)
37. Ito T, Ito N, Saathoff M, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008;128:1196-206. (Pubitemid 351543218)
38. Colombe BW, Price VH, Khoury EL, et al. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol 1995;33:757-64.
39. Tosti A, Duque-Estrada B. Treatment strategies for alopecia areata. Expert Opin Pharmacother 2009;10:1017-26.
40. Westerhof W, Njoo D, Menkes HE. Sudden whitening of hair. In: Nordlund JJ, Boissy RE, Hearing VJ, King R, Oetting W, Ortonne J-P, eds. The pigmentary system. 2nd ed. Malden, MA: Blackwell, 2006:764-6.
41. Tosti A, Whiting D, Iorizzo M, et al. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol 2008;59:64-7.
42. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010;62:177-88.
43. Tosti A, Colombati S, Caponeri GM, et al. Ocular abnormalities occurring with alopecia areata. Dermatologica 1985;170: 69-73. (Pubitemid 15164826)
44. Wiseman MC, Shapiro J, McDoland N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001;137:1063-8. (Pubitemid 32756464)
45. Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009;8:909-12.
46. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis: efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970;141: 193-202.
47. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003;49:96-8. (Pubitemid 36801639)
48. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005;52:287-90.
49. Luggen P, Hunziker T. High-dose intravenous corticosteroid pulse therapy in alopecia areata: own experience compared with the literature. J Dtsch Dermatol Ges 2008;6:375-8. (Pubitemid 351712825)
50. Goddard CJ, August PJ, Whorwell PJ. Alopecia totalis in a patient with Crohn's disease and its treatment with azathioprine. Postgrad Med J 1989;65:188-9. (Pubitemid 19069653)
51. Farshi S, Mansouri P, Safar F, Khiabanloo SR. Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study. Int J Dermatol 2010;49:1188-93.
52. Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979;115:1254-5. (Pubitemid 10153582)
53. Ohlmeier MC, Traupe H, Luger TA, Böhm M. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata - a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol 2011 May 14 (Epub ahead of print).
54. Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. BMJ 1983;287:1015-7. (Pubitemid 13009245)
55. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987;16:730-6. (Pubitemid 17031782)
56. Messenger AG, Slater DN, Bleehen SS. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br J Dermatol 1986;114: 337-47. (Pubitemid 16124178)
57. Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J Pathol 2010;177:2152-62.
58. Ferran M, Calvet J, Almirall M, Pujol RM, Maymó J. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: report of five cases and review of the literature. J Eur Acad Dermatol Venereol 2011;25:479-84.
59. Agesta N, Zabala R, Díaz-Pérez JL. Alopecia areata during interferon alpha- 2b/ribavirin therapy. Dermatology 2002; 205:300-1. (Pubitemid 36158545)
60. Kumar V, Pedroza LA, Mace EM, et al. The autoimmune regulator (AIRE), which is defective in autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy patients, is expressed in human epidermal and follicular keratinocytes and associates with the intermediate filament protein cytokeratin 17. Am J Pathol 2011; 178:983-8.
61. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009;27:363-91.
62. Duvic M, Hordinsky MK, Fiedler VC, O'Brien WR, Young R, Reveille JD. HLA-D locus associations in alopecia areata: DRw52a may confer disease resistance. Arch Dermatol 1991;127:64-8.
63. Tazi-Ahnini R, Cork MJ, Wengraf D, et al. Notch4, a non-HLA gene in the MHC is strongly associated with the most severe form of alopecia areata. Hum Genet 2003;112:400-3. (Pubitemid 36869068)
64. Tazi-Ahnini R, Cox A, McDonagh AJ, et al. Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1 in alopecia areata: strong severity association and possible gene interaction. Eur J Immunogenet 2002;29:25-30.
65. Sundberg JP, Silva KA, Li R, Cox GA, King LE. Adult-onset alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Dermatol 2004; 123:294-7. (Pubitemid 38951823)
66. Sun J, Silva KA, McElwee KJ, King LE Jr, Sundberg JP. The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results. Exp Dermatol 2008; 17:793-805.
67. Rodriguez TA, Fernandes KE, Dresser KL, Duvic M. Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors. J Am Acad Dermatol 2010;62:525-7.
68. Betz RC, König K, Flaquer A, et al. The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata. Br J Dermatol 2008;158:389-91.
69. Kemp EH, McDonagh AJ, Wengraf DA, et al. The non-synonymous C1858T substitution in the PTPN22 gene is associated with susceptibility to the severe forms of alopecia areata. Hum Immunol 2006;67:535-9. (Pubitemid 43994248)
70. Martinez-Mir A, Zlotogorski A, Gordon D, et al. Genome wide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007;80:316-28. (Pubitemid 46178387)
71. Muto M, Deguchi H, Tanaka A, Inoue T, Ichimiya M. Association between T-lymphocyte regulatory gene CTLA4 single nucleotide polymorphism at position 49 in exon 1 and HLA-DRB1*08 in Japanese patients with psoriasis vulgaris. J Dermatol Sci 2011;62:70-1.
72. Singh TP, Schön MP, Wallbrecht K, et al. 8-Methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/ Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010;184:7257-67.
73. John KK, Brockschmidt FF, Redder S, et al. Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol 2011;131:1169-72.
74. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010;466: 113-7.
75. Bodemer C, Peuchmaur M, Fraitaig S, Chatenoud L, Brousse N, DeProst Y. Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol 2000;114:112-6. (Pubitemid 30195982)
76. Kalish RS, Johnson KL, Hordinsky MK. Alopecia areata: autoreactive T cells are variably enriched in scalp lesions relative to peripheral blood. Arch Dermatol 1992;128:1072-7.
77. Dressel D, Brütt CH, Manfras B, et al. Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T-cell receptor-repertoire among infiltrating lymphocytes. J Cutan Pathol 1997;24:164-8. (Pubitemid 27117372)
78. Cetin ED, Savk E, Uslu M, Eskin M, Karul A. Investigation of the inflammatory mechanisms in alopecia areata. Am J Dermatopathol 2009;31:53-60.
79. Tobin DJ. Characterization of hair follicle antigens targeted by the anti-hair follicle immune response. J Investig Dermatol Symp Proc 2003;8:176-81. (Pubitemid 37222826)
80. Hedstrand H, Perheentupa J, Ekwall O, et al. Antibodies against hair follicles are associated with alopecia totalis in autoimmune polyendocrine syndrome type 1. J Invest Dermatol 1999;113:1054-8. (Pubitemid 30013352)
81. Gilhar A, Pillar T, Assy B, David M. Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice. Br J Dermatol 1992;126: 166-71.
82. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS. Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch Dermatol 2002;138:916-22. (Pubitemid 34700738)
83. Idem. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol 2001;117:1357-62.
84. McElwee KJ, Spiers EM, Oliver RF. In vivo depletion of CD8+T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 1996;135:211-7. (Pubitemid 26252968)
85. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 1993;66:541-54.
86. Siebenhaar F, Sharov AA, Peters EM, et al. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata). J Invest Dermatol 2007;127:1489-97. (Pubitemid 46766534)
87. Peters EM, Liotiri S, Bodó E, et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol 2007;171: 1872-86.
88. Stelekati E, Bahri R, D'Orlando O, et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity 2009;31:665-76.
89. Wade MS, Sinclair RD. Persistent depigmented regrowth after alopecia areata. J Am Acad Dermatol 2002;46:619-20.
90. Kang H, Wu WY, Lo BK, et al. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol 2010;130:2677-80.
91. Alli R, Nguyen P, Boyd K, Sundberg JP, Geiger TL. A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. J Immunol 2012;188:477-86.
92. Kinori M, Kloepper JE, Paus R. Can the hair follicle become a model for studying selected aspects of human ocular immune privilege? Invest Ophthalmol Vis Sci 2011;52:4447-58.